US20100286139A1 - Amino pyrazole compound - Google Patents

Amino pyrazole compound Download PDF

Info

Publication number
US20100286139A1
US20100286139A1 US12/742,302 US74230209A US2010286139A1 US 20100286139 A1 US20100286139 A1 US 20100286139A1 US 74230209 A US74230209 A US 74230209A US 2010286139 A1 US2010286139 A1 US 2010286139A1
Authority
US
United States
Prior art keywords
methyl
chloro
cells
pharmaceutically acceptable
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/742,302
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Liandong MA
Joshua Ryan Clayton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100286139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US12/742,302 priority Critical patent/US20100286139A1/en
Assigned to ELI LILLY AND COMPANY reassignment ELI LILLY AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURKHOLDER, TIMOTHY PAUL, CLAYTON, JOSHUA RYAN, MA, LIANDONG
Publication of US20100286139A1 publication Critical patent/US20100286139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • JAK2 Janus kinase 2
  • JAK2 has a pivotal role in the erythropoietin (EPO) signaling pathway, including erythrocyte differentiation and Stat5 activation.
  • EPO erythropoietin
  • Recent studies have demonstrated that patients with chronic myeloproliferative disorders such as polycythemia vera, essential thrombocytosis, and myelosclerosis with myeloid metaplasia and thrombotic disorders such as activated protein C resistance, splanchnic vein thrombosis, Budd-Chiari Syndrome, and portal vein thrombosis frequently have acquired activating mutations in JAK2.
  • mutant JAK2 leads to constitutive tyrosine phosphorylation activity, by an unknown mechanism.
  • the constitutive activity of mutant JAK2 leads to increased levels of phosphorylated JAK2, pSTAT5, and STAT5 transcriptional activity, which leads to the pathogenesis of myeloproliferative disorders and leukemias, such as atypical chronic myeloid leukemia.
  • JAK2 is activated by interleukin-6-depedent autocrine loop or other genetic alterations in solid and hematologic tumors, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, primary and secondary acute myeloid leukemia, T-lineage and B-lineage acute lymphoblastic leukemia, myelodysplasia syndrome.
  • interleukin-6-depedent autocrine loop or other genetic alterations in solid and hematologic tumors, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, primary and secondary acute myeloid leukemia, T-lineage and B-lineage acute lymphoblastic leukemia, myelodysplasia syndrome.
  • the present invention provides a novel amino pyrazole compound believed to have clinical use for treatment of myeloproliferative disorders in which the JAK2 signaling pathway is activated or in which JAK/STAT signaling is dysregulated.
  • the present invention provides 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating chronic myeloproliferative disorders selected from the group consisting of polycythemia vera, essential thrombocytosis, and myelosclerosis with myeloid metaplasia in a mammal comprising administering to a mammal in need of such treatment an effective amount of 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias, such as atypical chronic myeloid leukemia, primary and secondary acute myeloid leukemia, T-lineage and B-lineage acute lymphoblastic leukemia, myelodysplasia syndrome, and myeloproliferative disorders in a patient comprising administering to a patient in need of such treatment an effective amount of 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof.
  • leukemias such as atypical chronic myeloid leukemia, primary and secondary acute myeloid leukemia, T-lineage and B-lineage acute lymphoblastic leukemia, myelodysplasia syndrome, and myeloprolif
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • This invention also provides 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient in combination with another therapeutic ingredient.
  • This invention also provides 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof for use as a medicament. Additionally, this invention provides use of 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating chronic myeloproliferative disorders.
  • these chronic myeloproliferative disorders are selected from the group consisting of polycythemia vera, essential thrombocytosis, and myelosclerosis with myeloid metaplasia.
  • this invention provides a pharmaceutical composition for treating chronic myeloproliferative disorders selected from the group consisting of polycythemia vera, essential thrombocytosis, and myelosclerosis with myeloid metaplasia comprising 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the compound of the present invention is capable of forming salts.
  • the compound of the present invention is an amine, and accordingly reacts with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); L. D. Bighley, S. M. Berge, D. C. Monkhouse, in “Encyclopedia of Pharmaceutical Technology’. Eds. J. Swarbrick and J. C.
  • dimethicone during blending via a liquid addition system.
  • JAK2 EPO-TF1/pSTAT5 cell-based assay mimics the constitutive activation of JAK2-STAT5 in erythroid progenitor cells, which drives the overproduction of red blood cells, a marker of polycythemia vera (PV).
  • PV polycythemia vera
  • TF-1 human erythroid leukemia
  • RPMI-1640 was developed by Moore et. al. at Roswell Park Memorial Institute. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins.) with 10% fetal bovine serum (FBS), 0.075% sodium bicarbonate, 1 mM sodium pyruvate, 1 ⁇ antibiotic/antimycotic (Invitrogen, Carlsbad, Calif.) and 0.45% glucose.
  • FBS fetal bovine serum
  • the medium is supplemented with GM-CSF (granulocyte-macrophage colony-stimulating factor) at a final concentration of 2 ng/mL. Cells are kept at 37° C.
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • RPMI 1640 RPMI 1640 with 0.075% sodium bicarbonate, 1 mM sodium pyruvate, 1 ⁇ antibiotic/antimycotic, and 0.45% glucose
  • the diluted cells are added back to tissue culture flasks and incubated overnight at 37° C. Test compounds are prepared in 100% DMSO at 10 mM concentration.
  • EPO Erythropoietin
  • EPO medium is added into each well and the plate is vortexed.
  • Cells are incubated in a 37° C. water bath for 20 min and mixed every 5 min during the incubation time.
  • Final 10 point concentration-response range is 20 ⁇ M-1 nM at a final concentration of DMSO at 0.5% and EPO at 1.6 U/mL.
  • 500 ⁇ L of 1% formaldehyde solution (made freshly with phosphate-buffered saline (PBS) and kept warm at 37° C.) is added to each well. Plates are sealed and inverted 8-10 times to mix. Plates are placed in a 37° C. water bath for 10 min.
  • cell plates are spun at 1200 rpm for 5 min at room temperature (RT). The supernatant is aspirated, leaving 100 ⁇ L of cells (2 ⁇ 10 5 cells). The cells are vortexed and washed twice with 800 ⁇ L of PBS by repeating the spin steps and leaving 100 ⁇ L containing ⁇ 2 ⁇ 10 5 cells after the final wash. An aliquot of 800 ⁇ L of cold 90% methanol is added to the cells and placed at ⁇ 20° C. overnight. Plates are spun and methanol is removed. Cells are washed with FACS buffer (PBS with 5% FBS and 0.02% sodium azide).
  • FACS buffer PBS with 5% FBS and 0.02% sodium azide
  • IL-2 activates the JAK3 pathway in natural killer (NK) cells to drive the NK and CD8 lymphocyte proliferation. Therefore, IL-2 stimulated NK92/pSTAT5 cell-based assay enables the evaluation of the JAK3 cellular activity of JAK2 compounds in vitro.
  • NK-92 (natural killer) cells are maintained in minimum essential medium (MEM) Alpha with 15% fetal bovine serum, 15% Horse Serum and 1 ⁇ antibiotic/antimycotic (Invitrogen, Carlsbad, Calif.). The medium is supplemented with IL-2 (R&D systems, Minneapolis, Minn.) for a final concentration of 4 ng/mL. Cells are kept at 37° C. with 5% CO 2 . Cells are starved in serum free medium to remove endogenous growth factors. NK-92 cells are counted and collected to seed 2 ⁇ 10 7 cells per 96-well plate at a density of 2 ⁇ 10 5 cells per well.
  • MEM minimum essential medium
  • IL-2 R&D systems, Minneapolis, Minn.
  • the cells are rinsed twice with unsupplemented MEM Alpha (MEM Alpha) before suspending cells at a final concentration of 8 ⁇ 10 5 cells/mL in MEM Alpha with 0.6% serum (0.3% FBS, 0.3% horse serum).
  • MEM Alpha unsupplemented MEM Alpha
  • the diluted cells are added back to tissue culture flasks and incubated overnight at 37° C.
  • Test compounds are prepared in 100% DMSO at 10 mM concentration.
  • Compounds are serially diluted 1:3 with 100% DMSO in a 10 point-200 ⁇ concentration-response range (4 mM-200 nM).
  • 2.5 ⁇ L of 200 ⁇ compound solution is added to 125 ⁇ L of 10% FBS complete RPMI 1640 medium for a 4 ⁇ concentration compound plate.
  • serum-starved cells are collected and washed once with unsupplemented RPMI 1640 medium.
  • Cells are suspended in 10% FBS complete RPMI 1640 medium for a final concentration of 8 ⁇ 10 5 cells/mL.
  • An aliquot of 250 ⁇ L of diluted cells (2 ⁇ 10 5 cells) is added to each well in the 4 ⁇ concentration compound plate.
  • Cells are mixed by vortexing and the plate is incubated in a 37° C. water bath for 10 min.
  • a fresh 4 ⁇ working solution of IL-2 at 2 ng/mL is prepared using pre-warmed 10% FBS complete RPMI medium. After the cells are treated with compound for 10 min, 125 ⁇ L of IL-2 medium is added into each well. Cells are mixed by vortexing.
  • the supernatant is aspirated, leaving 100 ⁇ L of cells (2 ⁇ 10 5 cells).
  • the cells are vortexed and washed twice with 800 ⁇ L of PBS by repeating the spin steps and leaving 100 ⁇ L containing ⁇ 2 ⁇ 10 5 cells after the final wash.
  • An aliquot of 800 ⁇ L of cold 90% methanol is added to the cells and placed at ⁇ 20° C. overnight. Plates are spun and methanol is removed. Cells are washed with FACS buffer (PBS with 5% FBS and 0.02% sodium azide).
  • Cells are washed with PBS, and 50 ⁇ L of Cytofix® (BD Biosciences, San Jose, Calif.) is added to the cells. The cells are transferred to 96 well black tissue culture plates and sealed. The plates are spun down. Mean fluorescent intensity data are collected and analyzed using Cellomics Arrayscan® VTi. Compound treatment is compared to the vehicle to determine percent inhibition data. The MSR is determined to be 2.06. The relative IC 50 is calculated using a 4 parameter logistic curve fitting analysis with ActivityBase 4.0.
  • the ratio of JAK3/JAK2 was determined to be 28.5 fold, which demonstrates 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine is a selective JAK2 inhibitor over JAK3.
  • JAK2 target inhibition has been evaluated in Ba/F3 expressing JAK2 V617F by Western blot as reported in Wernig et al. (Wernig G, et al. Efficacy of TG 101348 , a selective JAK 2 inhibitor, in treatment of a murine model of JAK 2 V 617 F - induced polycythemia vera , Cancer Cell, April; 13(4):311-20).
  • a medium throughput Cellomics assay was established to evaluate the JAK2 target inhibition in Ba/F3 cells expressing JAK2V617F. This assay enables the discovery of an effective therapeutic agent to treat disorders associated with JAK2V617F mutation.
  • Ba/F3 (murine pro-B) cells expressing JAK2V617F maintained in RPMI 1640 with 10% FBS, 0.07% sodium bicarbonate, 1 mM sodium pyruvate, 1 ⁇ antibiotic/antimycotic (Invitrogen, Carlsbad, Calif.) and 0.45% glucose (Sigma, St Louis, Mo.). Cells are kept at 37° C. with 5% CO 2 .
  • the test compound is prepared in 100% DMSO at 10 mM concentration.
  • the compound is serially diluted 1:3 with 100% DMSO in a 10 point 200 ⁇ concentration-response range (4 mM-200 nM.).
  • 2.5 ⁇ L of 200 ⁇ compound solution is added to 125 ⁇ L of complete RPMI 1640 media with 10% FBS for a 4 ⁇ concentration compound plate.
  • cells are collected and washed twice with unsupplemented RPMI 1640. Cells are then suspended in 10% FBS completed RPMI medium for a final concentration of 4 ⁇ 10 5 /mL. Next, 500 mL of cells (2 ⁇ 10 5 cells) are transferred into 96 deep well plates. Finally, 2.5 ⁇ L (1:200 dilution) of compound stock solution are added to the cells and are incubated with cells in a 37° C. water bath for 60 min.
  • a working solution of 2 mg/mL Hoechst (Acros Organics, Morris Plains, N.J.) is prepared with PBS. An aliquot of 200 ⁇ L is added to each well and cells are incubated at RT in the dark for 10 min. Cells are washed with PBS, and 50 ⁇ L of Cytofix® (BD Biosciences, San Jose, Calif.) is added to the cells. The cells are transferred to 96 well black tissue culture plates and sealed. The plates are spun down. Mean fluorescent intensity data are collected and analyzed using Cellomics Arrayscan® VTi. Compound treatment is compared to the vehicle to determine percent inhibition data. The relative IC 50 is calculated using a 4 parameter logistic curve fitting analysis with ActivityBase 4.0.
  • the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration.
  • Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al., eds., 19 th ed., Mack Publishing Co., 1995).
  • the compounds of the present invention are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 1 mg to about 1000 mg total daily dose, preferably 500 mg to 1000 mg total daily dose, more preferably 600 mg to 1000 mg total daily dose.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed.
  • the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
US12/742,302 2008-12-16 2009-12-08 Amino pyrazole compound Abandoned US20100286139A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/742,302 US20100286139A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound
US12/742,302 US20100286139A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
US20100286139A1 true US20100286139A1 (en) 2010-11-11

Family

ID=41630090

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/742,302 Abandoned US20100286139A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound
US12/632,879 Expired - Fee Related US7897600B2 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/632,879 Expired - Fee Related US7897600B2 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Country Status (38)

Country Link
US (2) US20100286139A1 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
BR112013022697A2 (pt) * 2011-03-07 2019-09-24 Fond Telethon inibidores de fosforilação de tfeb e usos dos mesmos
WO2012172069A1 (en) * 2011-06-15 2012-12-20 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
ES2849974T3 (es) * 2016-11-17 2021-08-24 Bristol Myers Squibb Co Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083044A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20070191369A1 (en) * 2005-11-30 2007-08-16 Lauffer David J Inhibitors of c-Met and uses thereof
US20080085909A1 (en) * 2006-02-17 2008-04-10 Pharmacopeia Drug Discovery, Inc. Purinones and 1H-imidazopyridinones as PKC-theta inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345926B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
RU2325387C2 (ru) 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
EP1899329B1 (en) * 2005-07-01 2011-10-05 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1940847A2 (en) * 2005-10-06 2008-07-09 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
JP2010527999A (ja) 2007-05-23 2010-08-19 フアーマコペイア・エル・エル・シー ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083044A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20070191369A1 (en) * 2005-11-30 2007-08-16 Lauffer David J Inhibitors of c-Met and uses thereof
US20080085909A1 (en) * 2006-02-17 2008-04-10 Pharmacopeia Drug Discovery, Inc. Purinones and 1H-imidazopyridinones as PKC-theta inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Also Published As

Publication number Publication date
CO6331442A2 (es) 2011-10-20
PT2379557E (pt) 2013-01-14
AR074240A1 (es) 2011-01-05
JP2012512158A (ja) 2012-05-31
HN2011001697A (es) 2013-11-26
CN102232075B (zh) 2013-12-11
AU2009330503A1 (en) 2010-07-01
CY1113637T1 (el) 2016-06-22
TN2011000292A1 (en) 2012-12-17
PE20110549A1 (es) 2011-08-04
US7897600B2 (en) 2011-03-01
CA2744714A1 (en) 2010-07-01
NZ592641A (en) 2013-01-25
MX2011006441A (es) 2011-07-19
TWI440640B (zh) 2014-06-11
EP2379557A1 (en) 2011-10-26
JO2833B1 (en) 2014-09-15
EA019554B1 (ru) 2014-04-30
ZA201103942B (en) 2012-08-29
SG172202A1 (en) 2011-07-28
TW201024301A (en) 2010-07-01
PA8851101A1 (es) 2010-07-27
IL213065A0 (en) 2011-07-31
BRPI0923048A2 (pt) 2018-09-25
DK2379557T3 (da) 2012-12-17
KR101300458B1 (ko) 2013-08-30
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
UA104743C2 (ru) 2014-03-11
CR20110341A (es) 2011-07-13
JP5509217B2 (ja) 2014-06-04
EP2379557B1 (en) 2012-10-31
ES2396617T3 (es) 2013-02-22
EA201170831A1 (ru) 2011-12-30
ECSP11011132A (es) 2011-07-29
US20100152181A1 (en) 2010-06-17
KR20110084993A (ko) 2011-07-26
CN102232075A (zh) 2011-11-02
DOP2011000190A (es) 2011-07-31
WO2010074947A1 (en) 2010-07-01
PL2379557T3 (pl) 2013-03-29
SI2379557T1 (sl) 2013-02-28
CA2744714C (en) 2013-06-25
HK1160109A1 (en) 2012-08-10
AU2009330503B2 (en) 2012-06-07
CL2011001445A1 (es) 2011-11-11
HRP20120918T1 (hr) 2012-12-31
MY158691A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
US7897600B2 (en) Amino pyrazole compound
JP6698799B2 (ja) Ｆｇｆｒ抑制剤としての二環式複素環
CN115590854B (zh) 哒嗪基噻唑甲酰胺类化合物
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
KR102774784B1 (ko) Jak를 억제하기 위한 화합물 및 방법
TW201113285A (en) Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2669686A1 (en) 7-substituted purine derivatives for immunosuppression
HUP0401083A2 (hu) 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
MX2015005428A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
CN110891950B (zh) 一种三嗪化合物及其药学上可接受的盐
CZ139097A3 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
JP6092376B2 (ja) Ｊａｋ１およびｊａｋ２の阻害剤
CA3149846A1 (en) Quinoline derivatives as protein kinase inhibitors
HK1160109B (en) Amino pyrazole compound

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE